Systematic review of Pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer

Journal of Clinical Oncology

Volumn 27, Issue 3, 2009, Pages 398-403

  Vickers, Andrew J ^a   Savage, Caroline ^a   Frank O'Brien, M ^a   Lilja, Hans ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER RECURRENCE; CANCER SCREENING; CLINICAL DECISION MAKING; HUMAN; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; SYSTEMATIC REVIEW;

BIOPSY; HUMANS; MALE; MODELS, STATISTICAL; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 58549106592     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.18.1685     Document Type: Article

References (27)

1. Carter HB, Pearson JD, Metter EJ, et al: Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 267:2215-2220, 1992
2. Stephenson AJ, Scardino PT, Kattan MW, et al: Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 25:2035-2041, 2007
3. Dotan ZA, Bianco FJ Jr, Rabbani F, et al: Pattern of prostate-specific antigen (PSA) failure dictates the probability of a positive bone scan in patients with an increasing PSA after radical prostatectomy. J Clin Oncol 23:1962-1968, 2005
4. Oudard S, Banu E, Scotte F, et al: Prostate-specific antigen doubling time before onset of chemotherapy as a predictor of survival for hormone-refractory prostate cancer patients. Ann Oncol 18:1828-1833, 2007
5. Carter HB, Ferrucci L, Kettermann A, et al: Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst 98:1521-1527, 2006
6. Eggener SE, Roehl KA, Catalona WJ: Predictors of subsequent prostate cancer in men with a prostate specific antigen of 2.6 to 4.0 ng/ml and an initially negative biopsy. J Urol 174:500-504, 2005
7. Sengupta S, Myers RP, Slezak JM, et al: Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy. J Urol 174:2191-2196, 2005
8. D'Amico AV, Chen MH, Roehl KA, et al: Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 351:125-135, 2004
9. Khatami A, Aus G, Damber JE, et al: PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: Results from the European randomized study of screening for prostate cancer, Sweden section. Int J Cancer 120:170-174, 2007
10. National Comprehensive Cancer Network: Prostate cancer detection (version 1.2007). National Comprehensive Cancer Network, 2007. http://www.nccn.org
11. Ulmert DCA, O'Brien MF, Becker C, et al: Long-term prediction of prostate cancer: PSA velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population. J Clin Oncol 26:835-841, 2008
12. O'Brien MF, Fearn PA, Smith B, et al: Which definition of PSA doubling time or velocity best predicts outcome after radical prostatectomy? Presented at the Am Urol Assoc Annual Meeting, Anaheim, CA, May 19-24, 2007
13. Vickers AJ, Jang K, Sargent D, et al: A systematic review of statistical methods used in molecular marker studies in cancer. Cancer 112:1862-1868, 2008
14. Begg CB, Greenes RA: Assessment of diagnostic tests when disease verification is subject to selection bias. Biometrics 39:207-215, 1983
15. Thompson IM, Ankerst DP, Chi C, et al: Assessing prostate cancer risk: Results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 98:529-534, 2006
16. Loeb S, Roehl KA, Catalona WJ, et al: Prostate specific antigen velocity threshold for predicting prostate cancer in young men. J Urol 177:899-902, 2007
17. Djavan B, Zlotta AR, Byttebier G, et al: Prostate specific antigen density of the transition zone for early detection of prostate cancer. J Urol 160: 411-418; discussion 418-419, 1998
18. Djavan B, Zlotta A, Kratzik C, et al: PSA, PSA density, PSA density of transition zone, free/total PSA ratio, and PSA velocity for early detection of prostate cancer in men with serum PSA 2.5 to 4.0 ng/mL. Urology 54:517-522, 1999
19. Sun L, Moul JW, Hotaling JM, et al: Prostate-specific antigen (PSA) and PSA velocity for prostate cancer detection in men aged < 50 years. BJU Int 99:753-757, 2007
20. Moul JW, Sun L, Hotaling JM, et al: Age adjusted prostate specific antigen and prostate specific antigen velocity cut points in prostate cancer screening. J Urol 177:499-503; discussion 503-504, 2007
21. Ciatto S, Lombardi C, Rubeca T, et al: Predictors of random sextant biopsy outcome in screened men with PSA > 4 ng/mL and a negative sextant biopsy at previous screening: Experience in a population-based screening program in Florence. Int J Biol Markers 19:89-92, 2004
22. Lynn NN, Collins GN, O'Reilly PH: The short-term prostate-specific antigen velocity before biopsy can be used to predict prostatic histology. BJU Int 85:847-850, 2000
23. Ukimura O, Durrani O, Babaian RJ: Role of PSA and its indices in determining the need for repeat prostate biopsies. Urology 50:66-72, 1997
24. Berger AP, Deibl M, Strasak A, et al: Large-scale study of clinical impact of PSA velocity: Longterm PSA kinetics as method of differentiating men with from those without prostate cancer. Urology 69:134-138, 2007
25. Whittemore AS, Lele C, Friedman GD, et al: Prostate-specific antigen as predictor of prostate cancer in black men and white men. J Natl Cancer Inst 87:354-360, 1995
26. Barak M, Cohen M, Mecz Y, et al: The additional value of free prostate specific antigen to the battery of age-dependent prostate-specific antigen, prostate-specific antigen density and velocity. Eur J Clin Chem Clin Biochem 35:475-481, 1997
27. Perrin P: PSA velocity and prostate cancer detection: The absence of evidence is not the evidence of absence. Eur Urol 49:418-419, 2006